PNC-27
PNC-27 is an experimental peptide in basic cancer research, not an established cancer treatment.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
PNC-27 is the chimeric peptide defined in the primary study, combining a p53-derived HDM-2-binding domain with a membrane-penetrating sequence; commercial products remain analytically unconfirmed.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The source describes structural and cell effects in cancer cell lines and genetically modified cells outside the body.
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranesLaboratory study2010
Sarafraz-Yazdi E et al.
Accessed:
Research gaps
- ·Killing cells in a laboratory does not establish effective or safe cancer treatment. Clinical studies and independent replication are absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
Cell models examined binding to membrane-associated HDM-2 followed by membrane lysis.
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranesLaboratory study2010
Sarafraz-Yazdi E et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. Selectivity, off-target membrane injury, pharmacokinetics and toxicology have not been adequately studied in humans.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Killing cells in a laboratory does not establish effective or safe cancer treatment. Clinical studies and independent replication are absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranesLaboratory study2010
Sarafraz-Yazdi E et al.
Accessed:
Sources
Sources checked: · Version 3
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranesLaboratory study2010
Sarafraz-Yazdi E et al.
Accessed: